145 results about "Proinflammatory cytokine" patented technology

The invention discloses a novel nano-drug Res (at) LDH and a preparation method and application thereof.Germanium-doped LDH powder and resveratrol are combined to obtain a nanoscale particle mixed material Res (at) LDH, electron paramagnetic resonance (EPR) tests show that both the germanium-doped LDH and the traditional drug resveratrol show excellent reactive oxygen species (ROS) removal characteristics, and the Res (at) LDH can be used for preparing a novel nano-drug Res (at) LDH. The nano-drug Res (at) LDH formed by combining the two has remarkable synergistic ROS removal efficiency which can reach 90%. Meanwhile, in-vivo biological distribution experiments show that the novel nano-drug Res (at) LDH has excellent blood-brain barrier permeability, enhances accumulation in brain tissues, improves neurological dysfunction, reduces infarct volume, shows strong antioxidant activity, and inhibits release of pro-inflammatory cytokines.

The invention belongs to the technical field of microorganisms, and relates to a lactobacillus paracasei JNL0025 strain and application thereof. Compared with a commercial strain lactobacillus casei substitute strain, the lactobacillus paracasei JNL0025 provided by the invention has the advantages that the guanine nucleoside conversion rate is improved, the inhibition rate of supernate on XOD is equivalent, and the inhibition on PNP activity can be realized; according to the lactobacillus paracasei JNL0025 disclosed by the invention, the lactobacillus paracasei JNL0025 has the effects of reducing the tendency of pro-inflammatory M1 type macrophages, increasing the proportion of anti-inflammatory M2 type macrophages and inhibiting secretion of pro-inflammatory cytokines TNF-alpha and IL-6, and the lactobacillus paracasei JNL0025 has a better inflammation inhibition effect than the lactobacillus rhamnosus LGG; animal experiment results show that the lactobacillus paracasei JNL0025 provided by the invention can significantly reduce the blood uric acid level of a hyperuricemia model mouse, alleviate the kidney inflammation level and alleviate DSS-induced colitis, and shows a huge application value.

Provided are an anti-CD3 antibody or an antigen-binding fragment thereof, and a use thereof. The anti-CD3 antibody comprises: heavy chain variable region CDRs and light chain variable region CDRs, the heavy chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 1-3, 7-8 and 74-86 or a conservatively modified form thereof, and / or the light chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 4-6, 9 and 87-92 or a conservatively modified form thereof. The provided anti-CD3 antibody or antigen-binding fragment thereof can bind to human CD3 protein and reduce the production of pro-inflammatory cytokines, and a bispecific antibody constructed using same has high PBMC tumor-killing activity and weak promotion of the secretion of pro-inflammatory cytokines. A pharmaceutical composition prepared using the anti-CD3 antibody or the antigen-binding fragment thereof or a multi-specific antibody thereof has better safety, and has value for clinical applications and drug development.

The invention provides a lactobacillus plantarum 24 which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, and the preservation number of the lactobacillus plantarum 24 is CGMCC No.31278. The lactobacillus plantarum 24 has the advantages that the lactobacillus plantarum 24 is prepared from lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum and lactobacillus plantarum; the plant lactobacillus 24 disclosed by the invention can secrete sphingomyelinase and promote HaCaT cells to generate ceramide; the plant lactobacillus 24 or the metabolite or lysate thereof can up-regulate expression of key enzymes in a synthetic route of skin cell sphingomyelinase and / or ceramide, and repair a skin barrier; expression of proinflammatory cytokines is lowered, autophagy is inhibited, and a good anti-inflammatory effect is achieved; meanwhile, the anti-oxidation and whitening effects are relatively good. The plant lactobacillus 24 or the metabolite or the cell lysate of the plant lactobacillus 24 can be applied to preparation of products with the effects or the effects of the plant lactobacillus 24 and the metabolite or the cell lysate of the plant lactobacillus 24.

The invention belongs to the field of drug preparation, and particularly relates to a preparation method and application of a drug delivery system based on hollow mesoporous polydopamine nanoparticles. The drug delivery system comprises hollow mesoporous polydopamine nanoparticles, a drug loaded inside and / or outside the hollow mesoporous polydopamine nanoparticles, and pectin wrapping the hollow mesoporous polydopamine nanoparticles, the medicine is a medicine with a nerve protection effect and an acetylcholin esterase inhibitor. The drug delivery system can reduce proinflammatory cytokines, regulate functions of target immune cells, synergistically reduce necrosis of neurons in intestinal tracts and induce neural crest stem cells in the intestinal tracts to be differentiated into neurons.

The invention provides a bispecific antibody targeting CD3 and MICA and an application of the bispecific antibody. The present invention relates to a conjugate comprising: a first antigen binding region comprising an anti-CD3 antibody or an antigen binding fragment thereof; the present invention relates to an anti-CD3 antibody or an antigen-binding fragment thereof, comprising a first antigen-binding region having MICA binding activity, a second antigen-binding region having MICA binding activity, the anti-CD3 antibody or the antigen-binding fragment thereof comprising a first heavy chain variable region having a specific CDRs amino acid sequence and a first light chain variable region. The bispecific antibody disclosed by the invention can be combined with CD3 and MICA so as to promote T cell activation, secrete cell factors and effectively promote PBMC (peripheral blood mononuclear cells) to kill tumor cells, so that the bispecific antibody has good anti-cancer activity; moreover, the bispecific antibody has reduced proinflammatory cytokine secretion promotion performance and T cell activation promotion performance, is higher in safety, and has good clinical application value and drug development value.

The invention relates to the field of medicinal chemistry, and particularly discloses a piperidine derivative as well as a pharmaceutical composition, application and a preparation method thereof. The piperidine derivative has the following general formula. The piperidine derivative can be effectively used for treating or preventing multiple sclerosis, and shows an unexpected synergistic effect in an animal model: the piperidine derivative not only can significantly improve neurological function impairment and promote recovery, but also can deeply reduce the levels of key proinflammatory cytokines IFN-gamma and IL-17 at the same time. The invention provides a novel small molecule candidate drug with central permeability, neuroprotection and comprehensive immune regulation functions for treatment of multiple sclerosis.

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

The invention belongs to the technical field of engineered probiotics, and particularly relates to engineered probiotics for radiosensitization and tumor metabolism regulation as well as a preparation method and application of the engineered probiotics. The engineering probiotics comprise probiotics and core-shell type metal nanoparticles which are loaded on the probiotics and are synthesized through a biological directional mineralization effect; the core of the core-shell type metal nanoparticle is a palladium element, and the outer layer of the core-shell type metal nanoparticle is a palladium element and a gold element. The engineering probiotics provided by the invention have excellent enzyme catalysis performance and can target and retain in tumor sites, and through the synergistic effect of all components in the engineering probiotics, adenosine metabolism is effectively inhibited, secretion of pro-inflammatory cytokines is enhanced, tumor microenvironment is promoted to be converted into an inflammatory state, up-regulation of immune checkpoints is inhibited, and the immune checkpoints are inhibited. And T cells are inhibited from being transformed into depletion phenotype and transformed into effect type from depletion type. After the SBRT and the immune checkpoint inhibitor are combined for use, the growth of tumors can be effectively inhibited, and the effect of enhancing immune radiotherapy is achieved.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium animalis with a depression improving effect and application of the bifidobacterium animalis. Experimental results show that the bifidobacterium animalis CP-9 for preventing and relieving depression, provided by the invention, can reduce the content of proinflammatory cytokines in serum of depression mice. Therefore, the bifidobacterium animalis CP-9 has a good development prospect in the aspect of preparing products for preventing and / or treating depression or in the aspect of preparing products for reducing the content of pro-inflammatory cytokines in serum of depressive mice.

The invention belongs to the technical field of biological medicines, and particularly relates to a method for promoting polarization and phagocytosis of macrophages by using nicotine and application. It is found that 10 [mu] M nicotine promotes polarization of macrophages to M1 type macrophages and M2 type macrophages, the macrophages are induced to generate proinflammatory factors to regulate the functions of the macrophages, and phagocytosis of the macrophages is enhanced. The invention provides a new method for inducing polarization of macrophages, promoting the macrophages to generate pro-inflammatory cytokines and promoting phagocytosis of the macrophages, and provides a new idea for the new function and application of nicotine which is a tobacco active ingredient.

The invention discloses an adipose-derived stem cell exosome compound loaded with silver nanoparticles and application of the adipose-derived stem cell exosome compound loaded with the silver nanoparticles, and ADSC-Exos loaded with the silver nanoparticles is developed by integrating AgNPs into an exosome of ADSCs. In vivo, the Exo-AgNPs can accelerate healing of infected wounds by reducing bacterial colonization and promoting collagen deposition, angiogenesis and M2 type macrophage polarization. In vitro, the Exo-AgNPs activates the functions of fibroblasts and vascular endothelial cells, and shows an excellent antibacterial property. In addition, the Exo-AgNPs induces polarization of M2 type macrophages and inhibits secretion of proinflammatory cytokines by activating autophagy. The results show that Exo-AgNPs is expected to become an ideal biological material for treating infected wounds.

A use of a compound represented by formula I, or a cis-trans isomer, enantiomer, diastereomer, racemate, solvate, hydrate, pharmaceutically acceptable salt or prodrug thereof in the preparation of a drug for preventing, relieving, assisting in treating, or treating lung injury. Upon verification, administration of the compound represented by formula I can significantly reduce proinflammatory cytokines, i.e., tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), of a rat model of acute lung injury, reduce the infiltration of inflammatory cells (comprising monocytes / macrophages, lymphocytes, and neutrophils) in lung tissues, relieve pathological injury of the lung tissues, improve the lung function, and increase the survival rate of comorbidities of acute lung injury. The compound represented by formula I can be used for preventing, relieving, assisting in treating, or treating lung injury, especially acute lung injury or comorbidities thereof, or acute respiratory distress syndrome or comorbidities thereof.

The invention belongs to the field of biological medicine, and particularly relates to a CD3-LILRB4 bispecific antibody and application thereof. The invention provides a novel bispecific antibody with high activity and low toxicity, the bispecific antibody can be combined with CD3 and LILRB4 so as to promote T cell activation and effectively promote PBMC (peripheral blood mononuclear cells) to kill tumor cells, the bispecific antibody has good anti-cancer activity, and the bispecific antibody has the performance of reducing secretion of proinflammatory cytokines, is higher in safety, and can be applied to preparation of anti-tumor drugs. Good clinical application and drug development values are realized.

The invention provides a nano-micelle responding to an inflammation microenvironment as well as a preparation method and application of the nano-micelle. According to the nano-micelle, polyethylene glycol (PEG)-poly L-glutamic acid (PLG) is grafted with 4-hydroxymethyl phenylboronic acid (PBA), and the drug loading capacity of a hydrophobic anti-inflammatory drug is improved based on a hydrophobic effect and a borate bond formed by the PBA and a 1, 3-diol or 1, 2-diol structure of dexamethasone, curcumin and luteolin. The nano-micelle (PPDex micelle) has reversible splitting and rapid release behaviors under an inflammatory condition (the ROS level is increased or the pH value is reduced). The nano-micelle has a proper particle size, can effectively relieve inflammatory cell infiltration and pulmonary edema in the lung of an acute lung injury (ALI) mouse after pulmonary administration, reduces pro-inflammatory cytokines in the lung, inhibits oxidative stress, promotes polarization of macrophages from pro-inflammatory M1 phenotype to anti-inflammatory M2 phenotype, and finally inhibits the progress of ALI. The invention provides a novel effective anti-inflammatory strategy.

The invention discloses a compound microbial fermentation inoculant and application thereof in preparation of a metabiotic food taking multiple cereals as a matrix, and belongs to the technical field of microbial fermentation. According to the invention, a composite microbial fermentation inoculant is added into a multi-grain matrix containing a longan aril extract for fermentation, such that the post-generation food using multi-grain as the matrix is obtained. When the metabiotic food taking multiple cereals as the matrix is used for animal experiments, the blood pressure reduction rate of the compound group is higher, the fasting blood glucose value and the area under a curve are lower, the body weight and the TC value are smaller, the proinflammatory cytokines IL-1beta, IL-6 and TNF-alpha are smaller, and chao and ce indexes are larger. Compared with single use of the compound microbial fermentation inoculant, the longan aril extract or the multi-grain matrix, the metabiotic food which takes the multi-grain matrix and is obtained by the compound microbial fermentation inoculant has good effects of reducing blood pressure, reducing blood sugar and reducing blood fat, and can reduce inflammatory response, remove body toxins and regulate intestinal functions.

The invention provides application of injectable bioactive hydrogel in treatment of recurrent abortion, and relates to the technical field of biomedicine, and the technical key points are as follows: aldehydic hyaluronic acid and chitosan are connected in parallel, the injectable bioactive hydrogel is developed, and the hydrogel is loaded with LIF, VEGF, IL-11 and valproic acid to enhance regeneration activity. According to the application, the effect is evaluated in vitro through a specific verification experiment. Results show that the hydrogel prepared by the application shows rapid gelation, good biocompatibility and factor loading capacity, and enhances the proliferation of human endometrial stromal cells and the vascularization capacity of human umbilical vein endothelial cells. In macrophages, the expression of a proinflammatory cytokine is down-regulated, and the expression of an anti-inflammatory cytokine IL-10 is up-regulated. In conclusion, the HA-CHO / chitosan hydrogel in the application supports endometrial regeneration by synergistically promoting proliferation, angiogenesis, immune regulation and receptivity.

The invention provides a 3-hydroxypyrone derivative as well as a preparation method and application thereof, the compound can effectively inhibit release of proinflammatory cytokines in lipopolysaccharide-induced microglial cells, inhibit release of NO by the lipopolysaccharide-induced microglial cells, inhibit apoptosis of polysaccharide-induced microglial cells, and inhibit apoptosis of lipopolysaccharide-induced microglial cells. The compound has excellent anti-neuroinflammation activity and neuroprotective effect, the activity of the compound is superior to that of positive controls such as curcumin and hydrocortisone, and the compound can be used for preventing and / or treating neuroinflammation and neurodegenerative diseases.

Embodiments of the instant disclosure relate to intervention and / or treatment of autism spectrum disorder (ASD). Certain embodiments relate to treating a subject having ASD with one or more proinflammatory cytokines. In some embodiments, the one or more proinflammatory cytokines include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) or derivative thereof, or fusion polypeptide thereof, or recombinant thereof. Other embodiments include a mouse model for assessing efficacy of treatment of ASD in humans and other mammals.

Ligilactobacillus animalis and a use thereof. The Ligilactobacillus animalis is preserved in Guangdong Microbial Culture Collection Center on 13 October 2022, and the preservation number is GDMCC NO. 62867. The Ligilactobacillus animalis HHP002 can effectively inhibit the mRNA expression of proinflammatory cytokines of human colon cancer cells, thereby inhibiting generation of proinflammatory cytokines, and further inhibiting development of tumors, and the Ligilactobacillus animalis HHP002 can be applied to prevention and treatment of human colon cancer.

The invention relates to application of an organic compound in preparation of a medicine for preventing or treating neuroinflammation related diseases, and belongs to the technical field of medicinal chemistry. It is found that the organic compound with the chemical structural formula shown in the formula (I)-(IV) can remarkably inhibit the expression level of proinflammatory factors and chemotactic factors in a microglial cell inflammation model and has a broad-spectrum anti-inflammatory effect, and therefore the organic compound has the effect of preventing or treating neuroinflammation related diseases. The invention develops new application of the organic compounds as shown in the formulas (I)-(IV), and also provides a new therapeutic drug for preventing or treating neuroinflammation related diseases.

The present application discloses the application of MID1 as a marker and target for rheumatoid arthritis. The present application discloses that MID1 can be used as a diagnostic marker and therapeutic target for rheumatoid arthritis. By detecting the expression level of MID1, it can be used to diagnose rheumatoid arthritis. By knocking down the expression of MID1, the proliferation, invasion and metastasis of synovial fibroblasts can be inhibited, the secretion of proinflammatory cytokines can be inhibited, and the incidence of collagen-induced arthritis can be reduced.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for relieving depression and clearing collaterals and a preparation, a pharmaceutical composition and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 6-12 parts of radix bupleuri, 9-15 parts of radix curcumae, 6-12 parts of rhizoma acori graminei, 3-9 parts of fructus gardeniae, 3-9 parts of polygala tenuifolia, 9-15 parts of radix paeoniae rubra and 9-20 parts of cortex albiziae. The traditional Chinese medicine composition provided by the invention can be used for remarkably improving depression-like behaviors of mice with depression, reversing synaptic injury and improving the expression of synaptic associated proteins SYP and PSD-95. The anti-depression mechanism of the traditional Chinese medicine composition is that the traditional Chinese medicine composition has the effects of synergistically inhibiting activation of microglial cells and reducing the level of proinflammatory cytokines such as Tnf alpha, Il1beta and Il6, so that neuroinflammation is remarkably inhibited, and the traditional Chinese medicine composition has the advantages of novel formula, definite mechanism and definite curative effect for treating depression, particularly patients with anxiety and dysphoria symptoms.

The present application relates to the technical field of biological medicine engineering, and provides application of RBFOX2 inhibitor in treatment of inflammatory bowel disease, and particularly relates to the role of interfering RNA or antisense oligonucleotide or recombinant expression vector targeting RBFOX2 coding sequence in preparation of products for treating colitis and its related symptoms and / or other complications, and also relates to corresponding recombinant vectors or pharmaceutical compositions. The RBFOX2 inhibitor can effectively reduce the level of proinflammatory cytokines, inhibit the activation of macrophages, has effective application value in relieving and treating colonic inflammation and other symptoms and / or other complications of inflammatory bowel disease, provides a new target for treatment of inflammatory bowel disease, and has wide clinical application prospect.

The invention provides a formula food of a protein composition with an anti-inflammatory effect. The protein composition with the anti-inflammatory effect comprises alpha-whey protein and beta-casein, the mass ratio of the alpha-whey protein to the beta-casein is 1: (0.17-5). Compared with the prior art, the anti-inflammatory effect of alpha-whey protein and beta-casein in a ratio of 1: (0.17-5) is superior to that of monomers of alpha-whey protein and beta-casein, and the expression of macrophage proinflammatory cytokines is reduced, so that the inflammatory reaction is reduced; the inflammatory reaction is reduced by one or more of reducing the gene expression of tumor necrosis factor-alpha, reducing the gene expression of interleukin-1alpha and reducing the activation of a transcription activator, and the application prospect is wide when the compound is applied to the infant formula food.

Disclosed is a method for treating skin. The method can include topically applying to skin in need thereof a composition comprising effective amounts of Arctium lappa root extract and Epilobium angustifolium extract to reduce expression of a pro-inflammatory cytokine of IL-8, IL-2, or TNF-α in the skin.

A pomalidomide derivative exhibiting effects better than those of pomalidomide, a preparation method therefor, and use thereof. The pomalidomide derivative has excellent binding force to cereblon, has low cytotoxicity, has a low potential for causing teratogenic side effects, can regulate the expression of TNF-α and proinflammatory cytokines, and has excellent in vivo pharmacokinetic stability even while inhibiting oxidative stress.

The present invention belongs to the field of biomedicine technology, and specifically discloses the application of Lactobacillus delbrueckii surface protein in the preparation of products that improve intestinal inflammation. The new use of Lactobacillus delbrueckii surface protein provided by the present invention, including the application in the preparation of a medicine for preventing and / or treating ulcerative colitis. Cell and animal experimental results show that Lactobacillus delbrueckii surface protein can alleviate DSS-induced ulcerative colitis in mice, improve weight loss, shortened colon length and colon mucosal damage, reduce proinflammatory cytokine (such as IL-1β, IL-6) content in the colon, increase anti-inflammatory cytokine (such as IL-10) content, reduce proinflammatory macrophage ratio in spleen and colon, inhibit macrophage proinflammatory phenotype, can be used for the preparation of products that improve intestinal inflammation, and has good application prospects and potential clinical treatment value.

The invention relates to the field of biomedicine, and specifically relates to a recombinant antibody and a use thereof. A CD3 and FAP bispecific antibody binds weakly to T cells and binds strongly to FAP-positive cells, and has high killing activity, effectively enhancing the killing of FAP-positive cells by PBMCs and demonstrating good anticancer activity. In addition, the bispecific antibody has reduced ability to promote secretion of pro-inflammatory cytokines and T-cell activation, thereby improving safety.

The invention relates to pharmaceutics, and more particularly to gastroenterology, and can be used for the prophylaxis or treatment of inflammatory diseases of the gastrointestinal tract. What is described is the use of trimebutine maleate to achieve a maximum change in the level of the proinflammatory cytokines IL-1, IL-6, TNF-α, NF-κB and the anti-inflammatory cytokine IL-10 in the gastrointestinal tract for the prophylaxis or treatment of acute and chronic inflammatory diseases of the gastrointestinal tract.